Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J HoimesThomas W FlaigMatthew I MilowskyTerence W FriedlanderMehmet Asim BilenShilpa GuptaSandy SrinivasJaime R MerchanRana R McKayDaniel P PetrylakCarolyn SasseBlanca Homet MorenoYao YuAnne-Sophie CarretJonathan E RosenbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Enfortumab vedotin plus pembrolizumab showed a manageable safety profile. Most patients experienced tumor shrinkage. The median DOR and median OS exceeding 2 years in a cisplatin-ineligible patient population make this a promising combination currently under investigation in a phase III study (ClinicalTrials.gov identifier: NCT04223856).